Introduction
============

Bone fractures are one of the most common traumatic injuries in humans [@B1], especially among elders with advanced osteoporosis [@B2]. The time length of the fracture healing is an important factor in determining a patient\'s recovery rate and treatment cost [@B3]. Bone fracture heals normally in most patients; however, an overall 5 to 10% of bone fractures result in hypertrophic callus formation and delayed healing process [@B4].

Clinically, the fracture healing process is determined by patients\' health conditions, anatomic locations, as well as quality of the surrounding soft tissues. Temporary immobilization and surgical fixation are considered as the treatment choice for most fractures [@B5]. Unfortunately, many patients refused to undergo invasive operation due to the risk of non-union and delayed union [@B6]. There is a critical need to develop alternative strategies to promote fracture healing and repair.

Osthole (7-methoxy-8-isopentenoxycoumarin, C15H16O3, 244.39 Da) is a bioactive coumarin derivative [@B7]-[@B9] and has been used clinically in the treatment of kidney diseases [@B10]. Recently, several reports demonstrate that Osthole could prevent bone loss and promoting bone formation [@B11]-[@B13].

Fracture healing process is a specialized repair process that recapitulates aspects of embryonic skeletal development [@B14], [@B15]. During the healing process, both periosteal and endochondral ossification processes are involved in new bone formation and the latter process plays a more important role during fracture healing. In addition, multiple growth factor signaling pathways may be activated during fracture healing process [@B16], [@B17]. Among them, bone morphogenetic proteins (BMPs) play a more important role in fracture healing process. Recent studies suggest that BMP pathway is associated with the early phase in Osthole-induced osteoblast differentiation [@B18], [@B19]. In addition, Osthole induces endochondral ossification by up-regulation of mature osteoblast marker genes [@B20]. However, the underlying mechanism of Osthole-induced chondrocyte differentiation during fracture healing was not well characterized. Our current study aimed to investigate the *in vivo* effects and the molecular mechanisms by which Osthole promotes bone fracture healing.

Methods and Materials
=====================

1. Preparation of Osthole {#Section1}
-------------------------

Osthole (No. 110822-200305, purity \> 98%, 244.39 Da) (Figure [1](#F1){ref-type="fig"}A) was purchased from the National Institute for the Control of Pharmaceutical and Biological products (Beijing, China) and was dissolved in dimethylsulfoxide (DMSO) (less than 0.1%).

2. Experimental Animals {#Section2}
-----------------------

10-week-old male C57BL/6 mice were obtained from the animal center of the Zhejiang Chinese Medical University (Y2111184). They were divided into two groups: Osthole treatment group (30 mg/kg, local subcutaneous injection, daily for 28 days) [@B11] and vehicle control (PBS) group.

To generate chondrocyte specific *Bmp2* conditional KO mice, *Bmp2^flox/flox^* mice (obtained from Dr. Di Chen, Rush University, Chicago, USA) [@B21], [@B22] were bred with *Col2-Cre* transgenic mice. The *Col2-Cre* transgenic mice could efficiently target growth plate chondrocytes [@B23], [@B24]. All mice were under C57BL/6 background and mouse genotyping was determined by PCR using DNA extracted from tail biopsy tissues. PCR primer sequences for genotyping were as follows, MP1-600 F (A) 5\'-AGGGTTTCAGGTCAGTTTCCG, MP1-Hap-rv2 (B) 5\'-GATGATGAGGTTCTTGGCGG, and MP1-1615RW (C) 5\'-TCCGAAGGTAAGTGTGCTTGG. Cre-positive and *Bmp2^flox/flox^* male littermates were chosen as experimental groups while Cre-negative male littermates were used as controls (mean body weight 22 ± 2g). All mice had free access to food and water during the entire study.

3. Tibial Fracture Model {#Section3}
------------------------

In this study, a unilateral (right side) open transverse tibial fracture with intramedullary needle fixation was selected as the bone fracture model in 10-week-old C57BL/6, Cre-negative and *Bmp2^Col2Cre^* mice [@B22], [@B25], [@B26]. Anesthesia was induced with Ketamine (60 mg/Kg) via intraperitoneal injection. Next a 1.5cm-long incision was made along the anterior-medial surface and a 26 gauge syringe needle was inserted into the bone marrow cavity of the tibia through the tibial plateau on the medial side of the patellar ligament. Then the needle was removed, and a No. 11 surgical blade was used to transect the diaphysis of the tibia at the midpoint. A 26 gauge needle was then inserted into the tibia to stabilize the fracture. A 4-0 silk suture was used to close the wound and pain was managed using buprenorphine (in drinking water) for the first three days after surgery [@B26].

4. Radiographic and μCT Analyses {#Section4}
--------------------------------

After operation, X-ray radiographic analysis was performed immediately after fracture to ensure the fracture pattern and the position of the fixation needle. Mice were sacrificed at days 7, 10, 14, 21 and 28 for histological analysis after surgery (n=10 in each time point). Fracture healing was examined by the assessment of bridging across cortices. The extent of bridging between the fracture gap was determined in a blinded pattern by three independent investigators following the criteria: 1) grade 1: no healing (no indication or only some indications mineralized bridging); 2) grade 2: partial healing (more consolidated bridging or almost completely mineralized bridging); and 3) grade 3: complete healing (completely mineralized bridging). Specimens were scanned at 10.5-micron isotropic resolution using a micro-computed tomography (μCT) (Skyscan 1176; Bruker μCT, Kontich, Belgium) at each time points [@B26], [@B27]. Callus total volume (TV), callus bone volume (BV), callus mineralized volume fraction (BV/TV) (%) and callus bone mineral density (BMD) were determined (n=10 in each time point).

5. Biomechanical Testing {#Section5}
------------------------

Tibia bone samples were harvested and surrounding soft tissues were carefully removed (n=10 at days 10, 14, 21, and 28). Samples were fixed in aluminum square tubes (0.5 cm) filled with bone cement to make sure that fracture lines were in the middle of the interval. Specimens were mounted on an EnduraTec TestBenchTM system with a 200 N.mm torque cell (EnduraTec TestBenchTM system, Bose Corp., Minnetonka, MN) and tested in torsion at a rate of 10/sec until failure to determine maximum torque, stiffness and toughness of fracture callus [@B22].

6. Histology, Histomorphometry and Immunohistochemistry (IHC) {#Section6}
-------------------------------------------------------------

Bone samples were harvested (n=10 at days 7, 10, 14, 21 and 28) and fixed in 10% normal buffered formaldehyde for 3 days, decalcified in 14% EDTA solution for 14 days at room temperature and then embedded in paraffin. Tissue sections at the fracture site were cut longitudinally at thickness of 3-μm and prepared for Alcian blue/H&E staining and TRAP staining (day 14). Histomorphometric analysis (n=10 in each time point) was conducted using OsteoMetrics software (Decatur, GA). The mineralized volume of the cortices, the area of the periosteal calluses, and the mineralized and cartilaginous volume of the calluses were measured [@B22], [@B26]. The numbers of TRAP-positive multinucleated osteoclasts and percentage of osteoclast surface of the calluses were also measured. IHC was performed using anti-type II collagen (NeoMarkers, Inc. Fremont, CA, USA) and anti-pSmad1/5/8 (Santa Cruz Biotechnology, Santa Cruz, CA, USA) antibodies on the 3-μm thick tissue sections (days 7).

7. Quantitative Gene Expression Analysis {#Section7}
----------------------------------------

Total RNA was extracted from the callus tissue including adjacent bone on either side of the fracture line (1 mm) using the PureLink™ RNA Mini Kit (Invitrogen, Carlsbad, CA, USA) (n=6 in each time point). One microgram total RNA was used to synthesize cDNA using iScripts cDNA Synthesis Kit (Bio-Rad, Hercules, CA, USA). Real-time PCR amplification was performed using murine gene specific primers and SYBR green real-time PCR kit (Bio-Rad, Hercules, CA, USA). The levels of the target gene expression were normalized to that of *β-actin*. Expression levels of chondrogenic (*Sox9, Col2a1, Col10a1*) and osteogenic (*Runx2, osteocalcin*) marker genes was examined. Forward and reverse primers specific for the genes listed in Table [1](#T1){ref-type="table"}.

8. Cell Culture {#Section8}
---------------

Mouse chondrogenic ATDC5 cells (RIKEN Cell Bank, Tsukuba, Japan) were cultured in maintenance medium containing 1:1 Dulbecco\'s modified Eagle medium (DMEM)/F-12 medium (Sigma, St. Louis, MO, USA), supplemented with 5% fetal bovine serum (FBS), 100 U/mL penicillin,100 mg/mL streptomycin (Gibco, Grand Island, NY, USA), 1% L-glutamine (Gibco). After reaching 100% confluent, cells were centrifuged and then were plated in 12-well plates (Corning, NY, USA) at the center of each well for 2-3 h before adding chondrogenic differentiation medium (maintenance medium plus 10 μg/mL insulin, 10 μg/ml transferrin and 30 nM sodium selenite). All cells were maintained at 37°C in a humidified 5% CO~2~ incubator. The medium was changed every other day. After 2 days of culture, cells were treated with Osthole at concentrations of 0, 10, 50, 100 µM for one week (6 wells per group) [@B11]. Then total RNA was extracted and the levels of chondrogenic associated genes (*Sox9, Col2a1, Col10*) were analyzed.

9. Statistical Analysis {#Section9}
-----------------------

All values were presented as mean ± standard deviation. Statistical analyses included unpaired Student\'s *t*-tests and one-way ANOVA test followed by the Tukey-Kramer test. The statistical tests were performed using the software SPSS 17.0. *P* \< 0.05 was considered as significant.

Results
=======

Osthole Promotes Bone Fracture Healing in Mice
----------------------------------------------

Osthole (7-methoxy-8-isopentenoxycoumarin, C15H16O3, 244.39 Da) (Figure [1](#F1){ref-type="fig"}A) is an O-methylated coumarin isolated from plants such as Cnidium monnieri, Angelica archangelica and Angelica pubescens [@B29]. In the present studies, we examined the effect of Osthole on bone fracture healing. The results of radiographic analysis showed that administration of Osthole enhanced bone callus formation. Compared to the PBS control group, the presence of a fracture gap was blurry in Osthole treated group at days 10, 14 and 21 (Figure [1](#F1){ref-type="fig"}B and Table [2](#T2){ref-type="table"}).

Moreover, there was almost no fracture gap visible at day 28 in Osthole treated group, thus further confirming the beneficial role of Osthole on the normal fracture healing process (Figure [1](#F1){ref-type="fig"}B). In contrast the control group showed obvious fracture gap at the same time point. μCT data showed that the bone volume in Osthole-treated mice was increased compared to PBS control group at days 7, 10 and 14 (Figure [2](#F2){ref-type="fig"}A-C), supporting the radiographic findings. Results of biomechanical testing showed that treatment with Osthole enhanced bone mechanical strength (Figure [2](#F2){ref-type="fig"}D-F). The maximum torque and stiffness were significantly increased at days 10 and 14 in Osthole treated group compared to controls (Figure [2](#F2){ref-type="fig"}D and E).

Histologic and histomorphometric analyses showed that the progression of fracture healing was accelerated in Osthole-treated group. Cartilage area was determined by Alcian blue staining, which is significantly enlarged by day 7 in Osthole-treated mice (Figure [3](#F3){ref-type="fig"}A and B). The woven bone area was increased at days 7, 10 and 14 after surgery in Osthole-treated group (Figure [3](#F3){ref-type="fig"}A and C). The increase in cartilage area was supported by gene expression results showing that expression of the early cartilage marker genes such as *Sox9* and *Col2a1* were increased at day 7 in Osthole-treated group (Figure [4](#F4){ref-type="fig"}A and B). The levels of the later cartilage hypertrophic marker *Col10a1* were also increased at day 10 in Osthole-treated mice (Figure [4](#F4){ref-type="fig"}C). The expression of bone marker genes, *Runx2* and *osteocalcin* (*OCN*), was increased at day 21 in Osthole-treated group (Figure [4](#F4){ref-type="fig"}D and E). The changes in expression of cartilage and bone marker genes are consistent with the process and timing of endochondral ossification during the fracture healing process.

Osthole Promotes Bone Fracture Healing through BMP Signaling in Chondrocytes
----------------------------------------------------------------------------

Our findings suggest that Osthole can promote bone fracture healing by accelerating endochondral ossification. The expression of the type II collagen protein was further confirmed by IHC staining of the callus at day 7, with increased Col-II expression in Osthole-treated group (Figure [5](#F5){ref-type="fig"}A). Moreover, increased pSmad1/5/8 expression was detected at day 7 in Osthole-treated group (Figure [5](#F5){ref-type="fig"}B). Furthermore a mouse chondrogenic ATDC5 cells were used for *in vitro* experiments. Osthole promoted chondrogenesis in a dose-dependent manner (10-100 μM), as shown by the up-regulation of chondrocyte related marker genes such as *Sox9*, *Col2a1* and *Col10a1* (Figure [5](#F5){ref-type="fig"}C).

To determine if Osthole regulates osteoclast formation, we also performed TRAP staining in fracture callus at day 14. No significant changes in osteoclast numbers were found after Osthole treatment (Figure [6](#F6){ref-type="fig"}A-C), suggesting that Osthole has no significant effect on osteoclast formation during fracture healing.

To provide the definitive evidence about the role of *Bmp2* in Osthole-induced fracture healing, we examined the effect of Osthole on fracture healing in chondrocyte-specific *Bmp2* conditional KO mice. Radiographic data demonstrated that treatment with Osthole enhanced bone callus formation in Cre-negative group compared to the *Bmp2^Col2Cre^* group. The appearance of a fracture gap was blurry in Cre-negative group at earlier days 10, 14 and 21 than *Bmp2^Col2Cre^*group (Figure [7](#F7){ref-type="fig"} and Table [3](#T3){ref-type="table"}). At day 28, there was no obvious fracture gap in Cre-negative group. In contrast, obvious fracture gaps were seen in *Bmp2^Col2Cre^* group. These results indicate the essential role of BMP2 in Osthole-induced bone fracture healing process. μCT analysis demonstrated that the bone volume in Cre-negative control group was increased in response to Osthole treatment compared to *Bmp2^Col2Cre^*group at days 7, 10 and 14 (Figure [8](#F8){ref-type="fig"}A-C). In addition, the mechanical strength of the tibia was significantly decreased in *Bmp2^Col2Cre^* group, compared to the Cre-negative group in the presence of Osthole (*P*\< 0.05) (Figure [8](#F8){ref-type="fig"}D). The stiffness also significantly decreased at days 10 and 14 in *Bmp2^Col2Cre^* group, compared to Cre-negative control group in the presence of Osthole (Figure [8](#F8){ref-type="fig"}E). However, no significant effect was found on the stiffness and toughness at day 21 and 28 after Osthole treatment (Figure [8](#F8){ref-type="fig"}E, F).

Alcian blue/H&E stained sections from Cre-negative group and*Bmp2^Col2Cre^* group, both treated with Osthole, at day 7, 10, 14, 21 and 28, highlighted the characteristic differences in cartilage area of callus tissues and woven bone areas. Results of histologic and histomorphometric analyses revealed that fracture healing progress was delayed in *Bmp2^Col2Cre^*group. At day 7, cartilage area was significantly enlarged in Cre^-^ control group after Osthole treatment (Figure [9](#F9){ref-type="fig"}A and B). And woven bone area was increased at day 10 after surgery in Cre^-^ control group (Figure [9](#F9){ref-type="fig"}A and C). To further determine the role of BMP2 in Osthole-enhanced bone fracture healing, we analyzed the gene expression as well. Our results revealed that treatment with Osthole resulted in an increase in the expression of the early cartilage marker genes, such as *Sox9* and *Col2a1*, at day 7 and the later cartilage hypertrophic marker *Col10a1*at day 10 in Cre^-^ control mice (Figure [10](#F10){ref-type="fig"}A-C). The expression of bone marker *Runx2* was initially increased at day 10 in Cre^-^ control group (Figure [10](#F10){ref-type="fig"}D). In addition, Osthole did not affect the expression of bone marker *OCN* (Figure [10](#F10){ref-type="fig"}E). These results suggest that Osthole promotes bone fracture healing mainly through activation of BMP signaling during cartilage formation in callus tissue.

Discussion
==========

Osthole is a coumarin derivative that is present in many plants. These plants such as Cnidium monnieri and Angelica pubescens have been used as tonics and for the treatment of bone-related diseases [@B13], [@B30]. Osthole stimulates bone formation both *in vitro* and *in vivo* [@B11], [@B12]. In the present study, we demonstrated that Osthole promotes bone fracture healing and its effect on fracture healing could be inhibited when *Bmp2*was specifically deleted in chondrocytes. The results of the current study have identified the potential utility of Osthole in acceleration of fracture healing. The mechanism of Osthole-induced fracture healing may be partially related its role in activation of BMP signaling in chondrocytes.

Fracture healing can be temporally divided into an inflammatory phase, a soft callus phase, a hard callus phase, and a remodeling phase, and these stages show some overlap [@B31]. The bone repair process involves the coordination of multiple cell types to recover normal bone shape and function. Our data reveal that treatment with Osthole significantly accelerates the endochondral ossification in a fracture callus. Radiographic analysis showed that bridging of the fracture gap occurred at day 10 in Osthole-treated WT and Cre^-^ control mice, which was evidently earlier than that observed in *Bmp2^Col2Cre^*mice. Bone volume was significantly increased in Osthole-treated group, compared to the vehicle control group and *Bmp2^Col2Cre^*KO group at days 7, 10 and 14. These data are consistent with histologic and histomorphometric analyse, showing that Osthole enhances fracture healing at the early chondrogenesis phase. Osthole-treated mice exhibited a fracture callus with a larger cartilaginous compartment compared to control group and *Bmp2^Col2Cre^* KO group at day 7. The increased chondrogenic response was associated with increased gene expression of *Col2a1* and the protein expression of collagen II, a marker of cartilage formation at day 7. *Sox9* has been used as a marker for chondrogenic differentiation [@B32], [@B33] and it was upregulated at day 7 in Osthole-treated group. However, treatment with Osthole did not affect the expression of *Col2a1* and *Sox9* in *Bmp2^Col2Cre^* KO mice at the same time point. *Col10a1* is expressed in hypertrophic chondrocytes which could further undergo mineralization and apoptosis, connecting to subsequent angiogenesis and endochondral bone formation [@B34], [@B35]. At day 10, the expression of *Col10a1* was increased in Osthole-treated group, but not in *Bmp2^Col2Cre^* group.

We then analyzed expression levels of osteogenic marker genes, such as *Runx2* and *osteocalcin*. *Runx2* is a transcription factor playing important roles in chondrocytes and osteoblasts. *Osteocalcin* is mainly expressed in mature osteoblasts although it is also detected in hypertrophic chondrocytes. The expression of *Runx2* and *osteocalcin* was increased at day 21 when mice were treated with Osthole. Interestingly, between the two groups with Osthole treatment, the relative level of *Runx2* mRNA in Cre^-^ control group were significantly up-regulated than that of *Bmp2^Col2Cre^* group at day 10. Besides we utilized biomechanical testing and assessed maximal torque, stiffness and toughness. Stiffness reflects the elasticity of bone while maximal torque and toughness represent the forces and energy required to disrupt the callus. In our study, the results of maximal torque, stiffness and toughness reveal that Osthole enhances the mechanical strength of the bone fracture healing.

The findings presented above are consistent with our hypothesis that Osthole plays an important role during fracture healing by accelerating endochondral bone formation, especially during the chondrocyte differentiation and maturation. BMP2 plays an important role in chondrocyte differentiation and maturation [@B21]. BMP signaling pathway is known to regulate development and regeneration of bone and cartilage. BMPs elicit their function by binding to specific cell surface receptors with serine-threonine kinase activity and then inducing phosphorylation of receptor-regulated Smads (Smad1, 5, and 8) [@B36]. Smad1/5/8 specifically transduces BMP signal, overexpression of Smad1/5/8 in chondrocytes promotes chondrocyte maturation. Maturation of chondrocytes is a marked step in ossification. BMP2 promotes Smad1/5/8 phosphorylation and mediates Runx2 expression [@B37]. In our studies, the expression of pSmad1/5/8 was increased at day7 in Osthole-treated group, suggesting that Osthole promotes fracture healing through BMP2 signaling.

Therefore, we concluded that Osthole plays an important role in chondrocyte differentiation and maturation by regulating BMP2 signaling, and then influence endochondral ossification, thereby accelerating fracture healing.
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![Osthole promotes bone fracture healing in mice. (A) Chemical structure of Osthole. (B) Fracture procedure was performed in 10-week-old mice treated with vehicle or Osthole. X-ray radiographic analysis showed clear fracture lines at day 7- 21 in mice of control group, and blurry at day 10 and 14 in Osthole treated group, suggesting that fracture healing process is accelerated by Osthole. Red arrows indicate the fracture lines.](ijbsv13p0996g001){#F1}

![μCT and mechanical testing were performed in bone samples collected from mice 7, 10, 14, 21 and 28 days after surgery. (A-C) μCT analysis indicates that bone volume (%, BV/TV) was increased in callus tissues 7, 10 and 14 days after surgery in the mice treated with Osthole. (D-F) Mechanical testing showed that maximal torque (day 10 and 14) and stiffness (day 10 and 28) were significantly increased by the treatment with Osthole. Data are presented as means ± SD. \**P* \< 0.05, n=10.](ijbsv13p0996g002){#F2}

![Osthole increases cartilage and bone volume of fracture callus. (A) Histological analysis showed that Osthole accelerated the fracture healing process. (B) The Alcian blue staining positive cartilage area of callus tissues, (%, Cg.Ar/Ps.Cl.Ar) was increased after Osthole treatment at day 7 and slightly reduced at day 10. (C) New woven bone formation in callus tissues (%, Md.Ar/Ps.Cl.Ar) was enhanced by Osthole treatment at day 10-21. Black arrows: cartilage area; blue arrows: woven bone area. Data are presented as means ± SD. \**P*\< 0.05, n=10.](ijbsv13p0996g003){#F3}

![Osthole up-regulates expression of chondrocyte- and osteoblast-specific marker genes in callus tissues. Total RNA was extracted from callus tissues at day 7, 10, 14, 21 and 28 in the mice treated with or without Osthole. (A-C) Expression of *Sox9* and *Col2a1*was significantly increased at day 7; and expression of *Col10a1* was significantly increased at day 10. (D, E) Expression of *Runx2*was significantly increased at day 21 and 28, and expression of *osteocalcin*(*OC*) was significantly increased at day 21. Data are presented as means ± SD. \**P*\< 0.05, n=6.](ijbsv13p0996g004){#F4}

![Osthole promotes bone fracture healing through activation of BMP signaling in Chondrocytes. (A, B) Type II collagen protein and pSmad1/5/8 levels were significantly increased in Osthole treatment group (day 7). Black arrows: type II collagen-positive cells, and red arrows: pSmad1/5/8-positive cells. (C) A mouse chondrogenic cell line, ATDC5, was used to confirm the *in vivo* data. Osthole up-regulates chondrogenesis related genes, such as *Sox9*, *Col2a1* and *Col10a1,*especially at the concentration of 100 μM. Data are presented as means ± SD. *^\#^P*\< 0.05, 10 μM compared with 0 μM; ^❖^P \< 0.05, 50 μM compared with 0 μM; and \**P*\< 0.05, 100 μM compared with 0 μM.](ijbsv13p0996g005){#F5}

![Osthole had no significant effect on osteoclast formation during fracture healing. (A-C) TRAP staining was performed on day 14 callus tissues and showed no significant difference in osteoclast numbers and osteoclast surface percentage after Osthole treatment. Purple arrows: TRAP-positive multiple nuclear osteoclasts. Data are presented as means ± SD*,* n=6.](ijbsv13p0996g006){#F6}

![Osthole accelerated bone fracture healing in Cre-negative group compared with *Bmp2^Col2Cre^* group. X-ray radiographic analysis was performed on mice 7, 10, 14, 21 and 28 days after surgery. Clear fracture lines were found on radiographs at day 7-21 in *Bmp2^Col2Cre^* group, and were indistinguishable at day 10 and 14 in Cre-negative group. These data suggest that *Bmp2* is required for Osthole to promote bone fracture healing. Red arrows indicate the fracture lines.](ijbsv13p0996g007){#F7}

![Osthole-induced increases in bone volume and mechanical strength were inhibited in *Bmp2^Col2Cre^* KO mice. μCT analysis (A-C) and mechanical testing (D-F) were performed in Cre-negative and *Bmp2^Col2Cre^* KO mice 7, 10, 14 and 21 days after fracture procedure. Both Cre-negative and *Bmp2^Col2Cre^* KO mice were treated with Osthole. Bone volume and BV/TV (%) were significantly increased in callus tissues at day 7, 10 and 14 in Cre-negative mice treated with Osthole. In contrast, Osthole-induced increase in bone volume was inhibited in *Bmp2^Col2Cre^* KO mice (B, C). The effects of Osthole on maximal torque (day 10-28), stiffness (day 10 and 14), and toughness (day 10) were also inhibited in *Bmp2^Col2Cre^* group (D-F). Data are presented as means ± SD. \**P*\< 0.05, n=10.](ijbsv13p0996g008){#F8}

![The effects of Osthole on the increases in cartilage and bone volume in fracture callus were inhibited *Bmp2^Col2Cre^* KO mice. (A) Histological analysis showed that Osthole could not accelerate the fracture healing process for *Bmp2^Col2Cre^* group. (B) The Alcian blue staining positive cartilage area of callus tissues (%, Cg.Ar/Ps.Cl.Ar) was lower in *Bmp2^Col2Cre^* group compared with Cre-negative group after Osthole treatment at day 7. (C) New woven bone formation in callus tissues (%, Md.Ar/Ps.Cl.Ar) was lower in *Bmp2^Col2Cre^* group compared with Cre-negative group after Osthole treatment at day 10. Black arrows: cartilage area; blue arrows: woven bone area. Data are presented as means ± SD. \**P*\< 0.05, n=10.](ijbsv13p0996g009){#F9}

![Osthole-induced chondrocyte and osteoblast gene expression was also inhibited in *Bmp2^Col2Cre^* KO mice. (A-C) Expression of chondrocyte-specific genes, such as *Sox9* (day 7), *Col2a1* (day 7) and *Col10a1* (day 10), was significantly lower in *Bmp2^Col2Cre^* group compared with Cre-negative control group. (D) Expression of osteoblast-specific genes, such as *Runx2* (day 10), was also significantly lower in *Bmp2^Col2Cre^* group compared with Cre-negative control group. Data are presented as means ± SD. \**P*\< 0.05, n=6.](ijbsv13p0996g010){#F10}

###### 

Primer name and sequences for PCR analysis

  Primer Name             Sequences
  ----------------------- ----------------------------------
  *β-Actin* forward       5\'-GGAGATTACTGCCCTGGCTCCTA-3\'
  *β-Actin* reverse       5\'-GACTCATCGTACTCCTGCTTGCTG-3\'
  *Sox9* forward          5\'-GAGGCCACGGAACAGACTCA-3\'
  *Sox9* reverse          5\'-CAGCGCCTTGAAGATAGCATT-3\'
  *Col2a1* forward        5\'-TGGTCCTCTGGGCATCTCAGGC-3\'
  *Col2a1* reverse        5\'-GGTGAACCTGCTGTTGCCCTCA-3\'
  *Col10a1* forward       5\'-ACCCCAAGGACCTAAAGGAA-3\'
  *Col10a1* reverse       5\'-CCCCAGGATACCCTGTTTTT-3\'
  *Runx2*forward          5\'-GAGGGCACAAGTTCTATCTGGA-3\'
  *Runx2* reverse         5\'-GGTGGTCCGCGATGATCTC-3\'
  *Osteocalcin* forward   5\'-AGGGAGGATCAAGTCCCG -3\'
  *Osteocalcin* reverse   5\'-GAACAGACTCCGGCGCTA-3\'

###### 

Radiographic analysis of fracture gaps

            PBS Control (n=10)             Osthole (n=10)                     
  --------- -------------------- --------- ---------------- -- ---- --------- ----------
  Healing   No                   Partial   Complete            No   Partial   Complete
  d7        10                   0         0                   9    1         0
  d10       7                    3         0                   5    5         0
  d14       2                    8         0                   0    4         6
  d21       0                    6         4                   0    0         10

###### 

Radiographic analysis of fracture gap on Cre-negative and *Bmp2*^Col2Cre^ groups both with Osthole treatment

  Cre-negative Control with Osthole (n=10)       *Bmp2*^Col2Cre^with Osthole (n=10)                    
  ------------------------------------------ --- ------------------------------------ ---- -- ---- --- ---
  d7                                         9   1                                    0       10   0   0
  d10                                        5   5                                    0       8    2   0
  d14                                        0   4                                    6       4    5   1
  d21                                        0   0                                    10      1    6   3
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